CROI 2015 Program and Abstracts

Keyword Index

Superinfection; 259, 869 Suppression; 1023 Suppressive ART; 491 Surveillance; 234, 239, 601, 603, 607, 729, 1043, 1115 Surveillance data; 1001, 1064 Survival; 97, 578, 711, 1051, 1110, 1119 Sustainable; 1067 Sustained virologic response (SVR); 149, 643, 653, 654, 656, 657, 942 Symptomatic acute HCV infection; 14 Symptoms; 855, 1044 Synergy trial; 148 Syphilis; 304, 304, 839, 840, 841, 842, 848 Syrup; 955 System gaps; 911 Systems biology; 269 – T –

Therapeutic drug monitoring; 956 Therapeutic vaccine; 352 Therapy; 646, 646 Thrombocytopenia; 476 Thymus; 922 Time from HIV infection to viral suppression; 99 Time of infection; 599 Time to ART initiation; 581, 632LB Tissue; 425 • Factor; 268 • Macrophages; 380 • Resident; 425 TLR; 183

• Prophylaxis; 115LB TURQUOISE-I; 147 Type 1 interferon; 124, 188, 225, 292, 898 Type 2 diabetes; 758, 803 – U – UDL; 117 Uganda; 30, 317, 452, 454, 577, 1037, 1039, 1067

UGT1A1; 515 Ukraine; 1042 Ultradeep sequencing; 702, 785, 983 Ultrasensitive viral load; 564 Ultrasound; 932 UNAIDS 90-90-90; 1071 Undetectable HIV viral load; 438 Undiagnosed; 667 Undiagnosed HIV; 98, 1013, 1117 United States; 1052, 1057, 1060 Unplanned ART interruptions; 1015 Unprotected intercourse; 1024 Untranslated region; 169 Urine tenofovir assay; 975 URMC-099; 543 USA; 116, 242 – V – Vaccination; 353, 701, 945 Vaccine; 55LB, 64, 66, 163, 349, 905, 948 Vaccine response; 318 Vaccines; 216, 370 VACS; 487 VACS index; 746 Vaginal ring; 524, 992LB, 995 Varenicline; 139 Vascular; 475 Vascular disease; 760, 926 Vascular toxicity; 735 vCCL2 N-terminus peptide; 213 Verbal autopsy; 825 Vertical transmission; 937, 942 Vertically HIV-infected; 918 Veterans; 750, 750

TLR7; 417 TLR8; 282 TMAO; 755, 758 TNPO3; 196 Tolerability; 957 Topical PrEP efficacy; 963 Total DNA; 376 Toxicity; 792 TRAIL; 285 Trajectory; 494 Transinfection; 46LB Transcription; 413 Transcriptional networks; 172 Transcriptionally active proviruses; 912 Transcriptome; 324, 326 Transduction; 207 Transgendered; 1032 Transition to adult units; 918 Transmission; 209, 215, 217, 243, 247, 248, 250, 254, 672, 868, 869, 1115 • Biology; 126 • Cluster; 245, 246, 598 • Network; 120, 239, 240, 246 • Risk; 101, 816LB Transmitted drug resistance; 598, 599, 600, 601, 607 Transmitted founder; 44 Transmitted founder virus; 288, 364 Transmitted founder HIV-1; 54LB, 223 Transplantation; 70, 432 Transport; 519 Treatment; 78, 1114, 181, 690, 715, 828LB, 1023, 1114 • Access; 641 • As prevention; 27, 128, 180, 244, 989, 991LB, 1095, 1118

T cell; 46LB, 185, 210, 273, 284, 946 • Activation; 266, 267, 317, 928

• Exhaustion; 172 • Immunity; 281

• Receptor; 365 • Subsets; 267 T follicular; 166 T stem cell memory; 53 T-bet; 172 T-regulatory cells; 817 Tablets; 955 TAF; 113LB, 530 Tanzania; 606 Taq polymerase; 255 Targeted mutagenesis; 400 Targeted testing; 668 TasP; 24, 1115 Tat; 505 Tat inhibitor; 413 Tat mRNA; 412 TCA; 497 TCR Cloning; 365 TDR; 608 Telomere; 901 Telomere length; 306, 784, 881, 923 Temporal trends; 602, 729

VIA; 710 Vif; 193 VIH-1; 193 Violence; 102 Viral • Decay; 548 • Diversity; 612 • Fitness; 119 • Hepatitis; 708LB • Kinetic modeling; 148 • Kinetics; 393 • Load; 51, 864, 235, 314, 614, 617, 689, 841, 864, 886, 1023 • Load monitoring; 563, 619 • Persistence; 399 • Rebound; 58, 110LB, 168, 556, 560 • Replication; 49, 54LB • Reservoir; 108 • RNA biogenesis; 104LB • Sequences; 378 • Suppression; 98, 100, 154, 864, 294, 729, 854, 864, 887, 890, 996, 997, 1056, 1064, 1068, 1069 Viremia; 1004, 1049 Viremia copy years; 562 Virologic

Tenofovir; 23LB, 27, 113LB, 269, 511, 516, 517, 530, 596, 597, 765, 767, 768, 788, 791, 792, 794, 879, 953, 971, 986, 993, 994 • Alafenamide; 143LB, 795, 952 • Detection; 979 • Disoproxil fumarate; 143LB, 790, 793, 954, 981, 992LB • Gel; 26LB, 27, 982, 984 • PrEP; 984, 987 • Sparing; 766 Tenofovir/emtricitabine; 83, 525, 526, 566, 962, 972, 975 Test-seeking behavior; 1010 Testes; 534 Testing; 628, 1014, 1066, 1082, 1096, 1113 Tetherin; 122 Text message; 559 Tfh; 206, 947

• Continuum; 1006, 1070 • Experienced; 545, 644 • Failure; 571, 617, 1120 • Interruption; 110LB, 111LB, 1011 • Naive adults; 445, 550

• Outcomes; 659 • Response; 842 TREG; 274, 290 Trends; 850, 1060 TRIM32; 385

Trimethoprime; 512 Trimethylamine; 138 Tropism; 112LB, 219, 336, 564, 633 Truvada; 962

Keyword Index

Tfh cells; 49, 166, 326 TFV vaginal gel; 963 TFV-DP; 530

Tuberculosis (TB); 91, 130, 131, 810, 811, 813, 816LB, 821, 823, 825, 826, 827LB, 828LB, 829, 830, 831, 939, 940, 1108 • Diagnosis; 824

Th17; 206, 274 Th17 cells; 329 Thailand; 275, 276, 511 THC; 639 TheVeterans Aging Cohort Study index; 467

• In pregnancy; 822 • And HIV; 92, 822 • Meningitis; 826

691

CROI 2015